Lila Sciences Raises $350M Series A to Scale Scientific Superintelligence

Lila Sciences has raised $350M in Series A funding, bringing total capital raised to $550M following a previously announced $200M seed round. The Cambridge, Massachusetts-based company is developing scientific superintelligence through AI Science Factories, autonomous laboratory systems designed to accelerate discovery across life sciences, chemistry, and materials science. The financing was announced on October 9, 2025, and was initially co-led by Braidwell and Collective Global, with participation from investors including NVentures, Analog Devices, IQT, General Catalyst, Flagship Pioneering, ARK Venture Fund, Alumni Ventures, and March Capital.

Lila Sciences was founded in 2023 inside Flagship Pioneering by Noubar Afeyan, Geoffrey von Maltzahn, Molly Gibson, Jake Feala, Alex Sneider, and Ben Kompa. The company is led by CEO Geoffrey von Maltzahn and CTO Andrew Beam. The funding matters because it represents one of the largest bets yet on a new category emerging at the intersection of artificial intelligence, robotics, and scientific research: systems that do not simply analyze scientific data, but actively participate in generating it.

What Happened

A lot of AI companies promise intelligence. Lila Sciences is making a more expensive promise. The company raised $350M in Series A funding to expand its AI Science Factories, autonomous laboratory environments designed to conduct experiments across biology, chemistry, and materials science. Following its earlier $200M seed round, Lila Sciences has now secured $550M in total funding. The company emerged from stealth in 2025 after being incubated within Flagship Pioneering, the venture creation firm best known for helping launch Moderna and a series of breakthrough life science companies. According to Reuters, subsequent financing activity pushed the company's valuation above $1.3B, placing Lila Sciences among a growing class of heavily funded AI infrastructure companies.

Leadership reflects the scale of the ambition. CEO Geoffrey von Maltzahn, COO & CFO Jawad Ahsan, CTO Andrew Beam, Chief Revenue & Product Officer Jon Hennek, Chief Robotics Officer Julie Shah, Chief Autonomous Science Officer John Gregoire, and CSO, Physical Sciences Rafael Gómez-Bombarelli are leading a multidisciplinary effort that combines artificial intelligence, robotics, software systems, and scientific research under one roof. Those aren't titles assembled for a pitch deck. They're disciplines assembled for a mission.

Why This Matters

Scientific discovery has a speed problem. Not a talent problem. Not a capital problem. A speed problem. For decades, breakthroughs have depended on a cycle that remains stubbornly human: form a hypothesis, design an experiment, run the test, analyze the results, repeat. Even with advanced computing, the physical process of experimentation remains expensive and time-consuming. Scientific experimentation remains one of the largest cost centers in drug discovery, materials development, and industrial research.

Lila Sciences is pursuing a different model. Its platform combines AI systems with autonomous laboratory infrastructure capable of designing experiments, executing them, collecting results, and feeding that information back into future iterations. The objective is not simply faster analysis. The objective is faster discovery. Many AI companies operate inside existing pools of information, while Lila Sciences is attempting to create systems that generate entirely new information through experimentation. Investors appear willing to fund that distinction aggressively.

Market Context

The broader AI market spent much of the past 2 years focused on foundation models, copilots, and enterprise productivity software. Meanwhile, a quieter race has been unfolding around AI-for-Science.

Lila Sciences sits within the emerging AI-for-Science category, a market attracting increasing attention from venture capital firms, research institutions, and strategic technology investors. The opportunity spans pharmaceuticals, biotechnology, materials engineering, energy systems, advanced manufacturing, diagnostics, and climate technologies. Each of those sectors depends on experimentation, faces long development cycles, and represents markets measured in billions or trillions of dollars.

That reality helps explain the investor mix behind Lila Sciences. The cap table combines deep-tech investors, life science specialists, strategic technology players, and organizations with interests extending into national security and critical infrastructure. Investors including NVentures, NVIDIA's venture arm, signal growing confidence that AI's next major opportunity may extend beyond software and into scientific discovery itself. Cambridge, Massachusetts provides a fitting backdrop, as the region remains one of the world's most important intersections of biotechnology, academic research, venture capital, and artificial intelligence talent.

Competitive Landscape

Lila Sciences is operating in a rapidly expanding AI-for-Science ecosystem. Many companies focus on computational discovery, others specialize in laboratory automation, and others build software for scientific workflows. Lila Sciences is attempting to combine all 3 layers into a single operating system for science.

Scientific progress is often limited by disconnected systems. Models generate predictions, researchers validate them, laboratories execute experiments, and data moves between environments. Time disappears. Lila Sciences is pursuing tighter feedback loops where intelligence, experimentation, and learning operate as parts of the same system. The challenge is enormous, but so is the potential reward.

What This Signals

The significance of this funding round extends beyond a single company. Capital markets are beginning to differentiate between AI that organizes knowledge and AI that produces knowledge. That distinction may define the next phase of AI investment.

Large language models changed how information is accessed. The next frontier may involve systems capable of interacting with the physical world, generating experimental results, and contributing directly to scientific advancement. The market is increasingly rewarding companies operating at that intersection, and Lila Sciences represents one of the clearest examples yet.

A company founded in 2023 has already attracted more than half a billion dollars in funding because investors believe scientific discovery itself can become programmable. That's a remarkable statement about where venture capital believes the future is heading.

The Bigger Industry Shift

For years, discussions about artificial intelligence focused on replacing repetitive work. A different conversation is beginning to emerge: what happens when AI doesn't replace work, but accelerates humanity's ability to discover?

Healthcare breakthroughs, advanced materials, energy technologies, and new therapies have historically been constrained by the pace of experimentation. Lila Sciences is building around the idea that experimentation itself can evolve.

Whether the company ultimately achieves its vision remains an open question. Scientific history is filled with ambitious ideas that collided with reality. But the scale of investor commitment sends a clear signal. The race to build the future of science has moved from theory into infrastructure, and infrastructure is where serious markets are built.